The SV7 Impact Medicine Fund (IMF) mission is to turn scientific breakthroughs into successful biotech companies producing high impact precision medicine drugs for poorly treated diseases. Our portfolio investments have the potential to transform healthcare.
Precision medicine aims to deliver major, durable impact on drug safety and efficacy by providing patients with therapeutics targeted at their specific disease mechanisms with the ultimate intent to cure.
SV7 IMF focuses predominantly on early stage biotech investments and exploits SV’s extensive in-house experience of company creation, with investments in late preclinical and clinical stage companies representing a minority. As with SV’s predecessor funds, SV7 IMF will maximize the Fund’s potential to transform healthcare by working as trusted advisers and partners to the talented entrepreneurs of cutting-edge portfolio companies who create and build breakthrough companies and treatments.
We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.
Via a strategic partnership in the SV7 IMF, SV Health Investors and Cancer Research UK, the world’s largest independent funder of cancer research, have strengthened their previous collaboration to accelerate the development of cancer medicines. SV’s priority access to Cancer Research UK’s world-leading research provides the opportunity to rapidly develop and scale innovative research into new drugs.